In vitro activity of LY146032 (Daptomycin) against selected aerobic bacteria

J. H. Jorgensen, L. A. Maher, J. S. Redding

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


The in vitro activity of the new lipopeptide antibiotic LY146032 was generally four-fold greater (MIC 90 ≤ 0. 5 μg/ml) than that of vancomycin against methicillin-susceptible or methicillin-resistant Staphybcoccus aureus and coagulase-negative species of Staphylococcus. Enterococci, Streptococcus bovis, group B and viridans streptococci, and Corynebacterium group J-K isolates were inhibited by ≤ 4 μg/ml of LY146032, which represented activity equivalent to or greater than that of vancomycin. Unlike vancomycin, LY146032 was bactericidal for Enterococcus faecalis, Enterococcus faecium and Listeria monocytogenes. Due to its bactericidal properties LY146032 appeared to represent an improvement over vancomycin and teicoplanin.

Original languageEnglish (US)
Pages (from-to)91-96
Number of pages6
JournalEuropean Journal of Clinical Microbiology
Issue number1
StatePublished - Feb 1 1987

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)


Dive into the research topics of 'In vitro activity of LY146032 (Daptomycin) against selected aerobic bacteria'. Together they form a unique fingerprint.

Cite this